BPON-01 Tablets / TTYP01 Tablets
创建时间：2022-05-09 10:00
|
Name/Code number |
BPON-01 Tablets / TTYP01 Tablets |
|
Category |
505(b)2 |
|
Mode of Action (MOA) |
Free Radical Scavenger |
|
Formulation |
Tablets |
|
Strengths |
TBD |
|
Indication |
1. Acute Ischemic Stroke (AIS) 2. Amyotrophic Lateral Sclerosis (ALS) |
|
Stage |
Phase I (Australia and China) |
|
Characteristics/Advantages |
1.Based on the safety and effectiveness data of the marketed edaravone injection, and by changing the route of administration and formulation from an injection into an oral tablet
2.The phase 1 studies for AIS in Australia has completed, and a phase 1 bridging registration clinical application for AIS in China also has been approved
3.FDA approved the orphan drug qualification for ALS in 2021
4.Can provide patients with long-term treatment with better convenience and compliance
5.Global IP protection for formulations
|
|
Cooperation Model |
Out-license for global market outside of China |
